Recent developments of HSP90 inhibitors: an updated patent review (2020-present).
Jianfeng LiuHuangliang ShuQinxin XiaQi-Dong YouLei WangPublished in: Expert opinion on therapeutic patents (2024)
In the past few years, HSP90 inhibitors targeting ATP binding pocket are still predominate and one of them has been launched, besides, novel drug design strategies like C-terminal targeting, isoform selective inhibiting and bifunctional molecules are booming, aiming to improve the efficacy and safety. With expanded drug types and applications, HSP90 inhibitors may gradually becoming a sagacious option for treating various diseases.